Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)
A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib
Sponsor: Bayer
This PHASE3 trial investigates Gastrointestinal Stromal Tumors and is currently completed. Bayer leads this study, which shows 24 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
24 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 19 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
-
May 2020 — Jun 2020 [monthly]
Completed PHASE3
-
Jun 2019 — May 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Saarow, Germany , Barcelona, Spain , Beijing, China , Bologna, Italy , Bordeaux, France , Boston, United States , Busan, South Korea , Chuo-ku, Japan , Cologne, Germany , Düsseldorf, Germany and 45 more locations